TIMO is the first translational cancer-specific training program at the Medical University of Graz, which aligns with its long-standing tradition in cancer research. TIMO projects will focus on two hallmarks of cancer with great potential for novel therapeutic strategies and clinical applications: cancer cell metabolism and anti-tumour immunity. The core advantage of TIMO is the mutual co-supervision of the PhD candidates by preclinical and clinical principal investigators, paired based on their synergistic expertise on specific solid and blood cancer entities. This, together with an extended cancer-centered curriculum, will ensure a translational PhD education for both MDs and students with a master’s degree in science. Together with our PhD students we are poised to push the frontier in cancer research, paving the way for novel therapies and biomarkers.
- 15 paid PhD positions co-supervised by clinicians and basic researchers
- 4-year PhD education: October 2026 – September 2030
